PH12013500118A1 - Superior efficacy of cd37 antibodies in cll blood samples - Google Patents

Superior efficacy of cd37 antibodies in cll blood samples

Info

Publication number
PH12013500118A1
PH12013500118A1 PH1/2013/500118A PH12013500118A PH12013500118A1 PH 12013500118 A1 PH12013500118 A1 PH 12013500118A1 PH 12013500118 A PH12013500118 A PH 12013500118A PH 12013500118 A1 PH12013500118 A1 PH 12013500118A1
Authority
PH
Philippines
Prior art keywords
patients
treatment
antibodies
risk
cll
Prior art date
Application number
PH1/2013/500118A
Other languages
English (en)
Inventor
Karl-Heinz Heider
Stephan Stilgenbauer
Thorsten Zenz
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44546328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12013500118(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PH12013500118A1 publication Critical patent/PH12013500118A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PH1/2013/500118A 2010-07-16 2011-07-15 Superior efficacy of cd37 antibodies in cll blood samples PH12013500118A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10169795 2010-07-16
EP10175586 2010-09-07
PCT/EP2011/062133 WO2012007576A1 (en) 2010-07-16 2011-07-15 Superior efficacy of cd37 antibodies in cll blood samples

Publications (1)

Publication Number Publication Date
PH12013500118A1 true PH12013500118A1 (en) 2013-03-11

Family

ID=44546328

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2013/500118A PH12013500118A1 (en) 2010-07-16 2011-07-15 Superior efficacy of cd37 antibodies in cll blood samples

Country Status (15)

Country Link
US (3) US20120189618A1 (https=)
EP (2) EP2593479A1 (https=)
JP (2) JP2013538790A (https=)
KR (1) KR20130100918A (https=)
CN (2) CN105749276A (https=)
AU (1) AU2011278227B2 (https=)
BR (1) BR112013001012A2 (https=)
CA (1) CA2799036A1 (https=)
CL (1) CL2013000101A1 (https=)
EA (1) EA025365B1 (https=)
IL (1) IL222775A (https=)
MX (1) MX341463B (https=)
NZ (2) NZ603161A (https=)
PH (1) PH12013500118A1 (https=)
WO (1) WO2012007576A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20140196A1 (es) * 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
WO2013160396A1 (en) * 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
WO2013171287A1 (en) * 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
EP3283520B1 (en) 2015-04-13 2020-05-06 Pfizer Inc Chimeric antigen receptors targeting b-cell maturation antigen
WO2018132506A1 (en) 2017-01-10 2018-07-19 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
AU2018236450A1 (en) * 2017-03-16 2019-10-03 The General Hospital Corporation Chimeric antigen receptors targeting CD37
EP3601354A1 (en) 2017-03-31 2020-02-05 Genmab Holding B.V. Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
WO2019243636A1 (en) 2018-06-22 2019-12-26 Genmab Holding B.V. Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
MA53812A (fr) 2018-10-04 2021-08-11 Genmab Holding B V Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
EP4412715A1 (en) 2021-10-06 2024-08-14 Nordic Nanovector ASA Humanized hh1
AU2024362226A1 (en) 2023-10-18 2026-03-05 Debiopharm International S.A. Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
HRP20140338T1 (hr) * 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
JP2010532764A (ja) * 2007-07-06 2010-10-14 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
PE20140196A1 (es) * 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
EP2365003A1 (en) * 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
RU2526156C2 (ru) * 2008-11-13 2014-08-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Cd37-иммунотерапевтическая комбинированная терапия и ее применения

Also Published As

Publication number Publication date
US20120189618A1 (en) 2012-07-26
JP2017019800A (ja) 2017-01-26
EA201201660A1 (ru) 2013-07-30
CA2799036A1 (en) 2012-01-19
JP2013538790A (ja) 2013-10-17
IL222775A (en) 2017-10-31
EP3252077A1 (en) 2017-12-06
CN103003309A (zh) 2013-03-27
CL2013000101A1 (es) 2013-12-27
NZ603161A (en) 2015-02-27
CN105749276A (zh) 2016-07-13
WO2012007576A1 (en) 2012-01-19
NZ703225A (en) 2016-11-25
US20130236454A1 (en) 2013-09-12
EP2593479A1 (en) 2013-05-22
IL222775A0 (en) 2012-12-31
US20150266967A1 (en) 2015-09-24
EA025365B1 (ru) 2016-12-30
MX341463B (es) 2016-08-22
AU2011278227B2 (en) 2017-03-02
KR20130100918A (ko) 2013-09-12
BR112013001012A2 (pt) 2016-05-24
AU2011278227A1 (en) 2012-11-15
MX2012013613A (es) 2012-12-17

Similar Documents

Publication Publication Date Title
PH12013500118A1 (en) Superior efficacy of cd37 antibodies in cll blood samples
NZ574046A (en) Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
MX2019001414A (es) Angiogenesis utilizando celulas madre placentarias.
BR112014003117A2 (pt) inibidores da corrente funny (if) para uso em um método de tratamento e prevenção de insuficiência cardíaca em felino
MX2009005849A (es) Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
JP2013518815A5 (https=)
WO2012081898A3 (ko) 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
MX2015000863A (es) Anticuerpos anti-siglec-15.
WO2012142301A3 (en) Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
PH12017501075B1 (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
MX350010B (es) Inhibidores syk de imidazopiridinas.
NZ707292A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
MX365054B (es) Anticuerpo que reconoce el factor inhibidor de la leucemia humana (lif) y uso de anticuerpos anti-lif en el tratamiento de enfermedades asociadas a una proliferacion celular no deseada.
TN2014000337A1 (en) Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status
EA201390335A1 (ru) Введение лоркасерина индивидуумам с почечной недостаточностью
MX2010010799A (es) Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
UA116615C2 (uk) Застосування ондансетрону у лікуванні хвороби чи розладу, пов'язаних з алкоголем
WO2008039409A8 (en) Methods and kits for use in the treatment and prevention of diseases or conditions of the immune system or infectious diseases
WO2010102160A3 (en) Diagnostic method using palb2
WO2011118928A3 (ko) 심부전 예방 또는 치료용 약제학적 조성물 및 심부전 예방 또는 치료제의 스크리닝 방법
KR20180095093A (ko) 뇌 신경 교종 치료용 약물 제조에서의 화합물의 용도
WO2010124239A3 (en) Genetic polymorphisms associated with clinical outcomes of topoisomerase inhibitor therapy for cancer
WO2016149485A1 (en) Novel chemoimmunotherapy for epithelial cancer
Aghamiri et al. 7SK-enriched exosomes suppress the cancer phenotypes in human lung cancer cells: insights from 2D and microfluidic 3D in vitro models
MX2014002307A (es) Metodo para predecir el riesgo de hipertension asociado a la terapia antiangiogenesis.